Answers are grounded in this paper and cite their sources.
Current guidelines from the American College of Chest Physicians, based on evidence from clinical trials, recommend that patients with venous thromboembolism (VTE) be treated initially with heparin, followed by long-term treatment with a vitamin K antagonist (VKA) [1]. However, patients with active cancer are often excluded from clinical trials of anticoagulant therapy because of short life expectancy, inability or unwillingness to attend for regular laboratory monitoring during VKA therapy, or contraindications to therapy, which means that treatment regimens based on the results from clinical trials might not be suitable for many VTE patients with cancer.
No takes yet. Share an insight, caveat, or question.
Monréal et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: